Literature DB >> 28656029

Updates to the Rome Criteria for Irritable Bowel Syndrome.

Lin Chang1.   

Abstract

Entities:  

Year:  2017        PMID： 28656029      PMCID： PMC5479345     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  4 in total

Review 1.  Irritable bowel syndrome: what do the new Rome IV diagnostic guidelines mean for patient management?

Authors:  William E Whitehead; Olafur S Palsson; Magnus Simrén
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2017-02-22       Impact factor: 3.869

Review 2.  A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS.

Authors:  Stacy B Menees; Corey Powell; Jacob Kurlander; Akash Goel; William D Chey
Journal:  Am J Gastroenterol       Date:  2015-03-03       Impact factor: 10.864

3.  Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV.

Authors:  Douglas A Drossman
Journal:  Gastroenterology       Date:  2016-02-19       Impact factor: 22.682

4.  Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects.

Authors:  Mark Pimentel; Walter Morales; Ali Rezaie; Emily Marsh; Anthony Lembo; James Mirocha; Daniel A Leffler; Zachary Marsh; Stacy Weitsman; Kathleen S Chua; Gillian M Barlow; Enoch Bortey; William Forbes; Allen Yu; Christopher Chang
Journal:  PLoS One       Date:  2015-05-13       Impact factor: 3.240
  4 in total
  2 in total

1.  Improving the Treatment of Irritable Bowel Syndrome With the Rome IV Multidimensional Clinical Profile.

Authors:  Douglas A Drossman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-11

2.  Association between Endometriosis, Irritable Bowel Syndrome and Eating Disorders: ENDONUT Pilot Study.

Authors:  Alexandra Aupetit; Sébastien Grigioni; Horace Roman; Moïse Coëffier; Amélie Bréant; Clotilde Hennetier; Najate Achamrah
Journal:  J Clin Med       Date:  2022-09-29       Impact factor: 4.964
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.